{"id":741158,"date":"2025-04-28T15:00:02","date_gmt":"2025-04-28T15:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=741158"},"modified":"2025-04-28T15:00:02","modified_gmt":"2025-04-28T15:00:02","slug":"plantar-fasciitis-pipeline-analysis-clinical-trials-2025-plantar-fasciitis-treatment-market-by-delveinsight-mimedx-revance-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/plantar-fasciitis-pipeline-analysis-clinical-trials-2025-plantar-fasciitis-treatment-market-by-delveinsight-mimedx-revance-therapeutics_741158.html","title":{"rendered":"Plantar Fasciitis Pipeline Analysis, Clinical Trials, 2025 | Plantar Fasciitis Treatment Market by DelveInsight | Mimedx, Revance Therapeutics"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/04\/1745744432.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Plantar Fasciitis Pipeline Analysis, Clinical Trials, 2025 | Plantar Fasciitis Treatment Market by DelveInsight | Mimedx, Revance Therapeutics\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/04\/1745744432.jpg\" alt=\"Plantar Fasciitis Pipeline Analysis, Clinical Trials, 2025 | Plantar Fasciitis Treatment Market by DelveInsight | Mimedx, Revance Therapeutics\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Plantar Fasciitis Pipeline Insights, 2025<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Plantar Fasciitis Pipeline constitutes 3+ key companies continuously working towards developing 3+ Plantar Fasciitis treatment therapies, analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\"><strong>Plantar Fasciitis Disease Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">Plantar fasciitis is one of the most common reasons for heel pain. The plantar fascia is a thick, web-like ligament that links the heel bone to the front of the foot. It plays a crucial role in walking by acting as a shock absorber and supporting the foot&rsquo;s arch. Over time, daily activities can cause significant strain on this ligament, leading to inflammation, which results in heel pain and stiffness.<\/p>\n<p style=\"text-align: justify;\"><strong>Download our report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/plantar-fasciitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/plantar-fasciitis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/plantar-fasciitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Plantar Fasciitis Pipeline Insight 2025<\/a>&#8221; report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Plantar Fasciitis Therapeutics Market. <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Plantar Fasciitis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>DelveInsight&rsquo;s Plantar Fasciitis pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Plantar Fasciitis treatment.<\/p>\n<\/li>\n<li>\n<p>The FDA expanded ActiPatch&reg;&#8217;s OTC clearance to encompass general musculoskeletal pain, broadening its application beyond specific conditions.<\/p>\n<\/li>\n<li>\n<p>The FDA granted 510(k) clearance for Erchonia&#8217;s FX 635 low-level laser device for the temporary relief of chronic musculoskeletal pain. This clearance was based on clinical trials demonstrating significant pain reduction in patients.<\/p>\n<\/li>\n<li>\n<p>Key Plantar Fasciitis companies such as Mimedx, Revance Therapeutics, and others are evaluating new drugs for Plantar Fasciitis to improve the treatment landscape.<\/p>\n<\/li>\n<li>\n<p>Promising Plantar Fasciitis therapies are Micronized dHCAM, DAXI, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Plantar Fasciitis Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The Plantar Fasciitis pipeline insights report 2025, provides insights into:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Provides comprehensive insights into key companies developing therapies in the Plantar Fasciitis Market.<\/p>\n<\/li>\n<li>\n<p>Categorizes Plantar Fasciitis therapeutic companies by development stage: early, mid, and late-stage.<\/p>\n<\/li>\n<li>\n<p>Highlights major companies involved in targeted therapy development, including both active and inactive (paused\/discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Reviews emerging Plantar Fasciitis drugs under development based on:<\/p>\n<ul>\n<li>\n<p>Stage of development<\/p>\n<\/li>\n<li>\n<p>Plantar Fasciitis Route of administration<\/p>\n<\/li>\n<li>\n<p>Target receptor<\/p>\n<\/li>\n<li>\n<p>Monotherapy vs. combination therapy<\/p>\n<\/li>\n<li>\n<p>Plantar Fasciitis Mechanism of action<\/p>\n<\/li>\n<li>\n<p>Molecular type<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>Offers detailed analysis of:<\/p>\n<ul>\n<li>\n<p>Company-to-company and company-academia collaborations<\/p>\n<\/li>\n<li>\n<p>Plantar Fasciitis Licensing agreements<\/p>\n<\/li>\n<li>\n<p>Funding and investment activities supporting future Plantar Fasciitis market advancement.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Request for a sample report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/plantar-fasciitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/plantar-fasciitis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Plantar Fasciitis Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Micronized dHCAM: Mimedx<\/p>\n<\/li>\n<li>\n<p>DAXI: Revance Therpaeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Plantar Fasciitis Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Around three major companies are currently developing therapies for Plantar Fasciitis. Among them, Mimedx and a few others have drug candidates in the mid to late stages of development, specifically in Phase II and Phase III clinical trials.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s report covers around 140+ products under different phases of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/plantar-fasciitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Plantar Fasciitis clinical trials<\/a> like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Plantar Fasciitis Late stage Therapies (Phase III)<\/p>\n<\/li>\n<li>\n<p>Plantar Fasciitis Mid-stage Therapies (Phase II)<\/p>\n<\/li>\n<li>\n<p>Plantar Fasciitis Early-stage Therapies (Phase I)<\/p>\n<\/li>\n<li>\n<p>Plantar Fasciitis Pre-clinical and Plantar Fasciitis Discovery stage Therapies<\/p>\n<\/li>\n<li>\n<p>Plantar Fasciitis Discontinued &amp; Inactive Therapies<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Plantar Fasciitis pipeline report provides the Plantar Fasciitis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Intramuscular<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Plantar Fasciitis Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Monoclonal antibody<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download Sample Pages to Get an in-depth Assessment of the Emerging Plantar Fasciitis Therapies and Key Plantar Fasciitis Companies: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/plantar-fasciitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Plantar Fasciitis Clinical Trials and recent advancements<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Plantar Fasciitis Pipeline Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Plantar Fasciitis Assessment by Product Type<\/p>\n<p style=\"text-align: justify;\">&bull; Plantar Fasciitis By Stage<\/p>\n<p style=\"text-align: justify;\">&bull; Plantar Fasciitis Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">&bull; Plantar Fasciitis Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Plantar Fasciitis Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Plantar Fasciitis &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Plantar Fasciitis Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Plantar Fasciitis Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Plantar Fasciitis Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Plantar Fasciitis Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Plantar Fasciitis Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Plantar Fasciitis Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Plantar Fasciitis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Plantar Fasciitis Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Plantar Fasciitis Analyst Review<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=plantar-fasciitis-pipeline-analysis-clinical-trials-2025-plantar-fasciitis-treatment-market-by-delveinsight-mimedx-revance-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=plantar-fasciitis-pipeline-analysis-clinical-trials-2025-plantar-fasciitis-treatment-market-by-delveinsight-mimedx-revance-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Plantar Fasciitis Pipeline Insights, 2025 Plantar Fasciitis Pipeline constitutes 3+ key companies continuously working towards developing 3+ Plantar Fasciitis treatment therapies, analyzes DelveInsight. Plantar Fasciitis Disease Overview: Plantar fasciitis is one of the most common reasons for heel pain. The &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/plantar-fasciitis-pipeline-analysis-clinical-trials-2025-plantar-fasciitis-treatment-market-by-delveinsight-mimedx-revance-therapeutics_741158.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-741158","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/741158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=741158"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/741158\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=741158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=741158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=741158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}